In a systematic literature review of patients with pulmonary arterial hypertension, 75% of assessed transitions from parenteral, inhaled, or oral prostacyclin pathway agents to oral selexipag were deemed successful.
Systematic Review (n=403)
Is transitioning from parenteral, inhaled, or oral prostacyclin pathway agents to oral selexipag a feasible and safe strategy in adult patients with pulmonary arterial hypertension?
Transitioning from parenteral, inhaled, or oral prostacyclin pathway agents to oral selexipag is feasible in PAH patients when individualized protocols and shared decision-making are utilized.
This review highlights cases where oral selexipag may be a suitable option when clinicians and patients participate in shared decision-making considering safety and risks/benefits. Transitions should be individualized based on clinical assessment, with appropriate monitoring and follow-up.
Elwing et al. (2026) conducted a systematic review in Pulmonary Arterial Hypertension (n=403). Oral selexipag vs. Prior prostacyclin pathway agents (treprostinil, epoprostenol) was evaluated on Transition success (as defined by individual study authors). In a systematic literature review of patients with pulmonary arterial hypertension, 75% of assessed transitions from parenteral, inhaled, or oral prostacyclin pathway agents to oral selexipag were deemed successful.